Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results
October 19, 2020 14:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
September 09, 2020 15:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update
August 05, 2020 07:00 ET
|
Constellation Pharmaceuticals , Inc.
Constellation has aligned with the FDA on the design of MANIFEST-2, the pivotal Phase 3 clinical trial for CPI-0610 expected to begin in 2H20Constellation plans to explore additional indications for...
Constellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 Results
July 31, 2020 12:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise
June 12, 2020 02:30 ET
|
Constellation Pharmaceuticals , Inc.
Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of careSpleen responses demonstrated in...
Constellation Pharmaceuticals to Participate in Investor Conference
May 29, 2020 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces First-Quarter 2020 Financial Results
May 06, 2020 07:00 ET
|
Constellation Pharmaceuticals , Inc.
EHA abstracts to publish on May 14 with an interim update across the MANIFEST trial cohortsConstellation to provide an additional interim update from MANIFEST at EHA in mid-June Company continues to...
Constellation Pharmaceuticals to Participate in Two Investor Conferences
May 05, 2020 14:06 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2020 Results
April 28, 2020 09:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results
March 10, 2020 16:12 ET
|
Constellation Pharmaceuticals , Inc.
Clinical data presented at 2019 American Society of Hematology (ASH) annual meeting suggested that CPI-0610 could offer meaningful benefits beyond standard of care in myelofibrosis In addition to...